Trial intelligence / Profile preview

MK-8457 in active rheumatoid arthritis after inadequate response or intolerance to anti-TNF-alpha therapy

2012-002181-12Phase 2Completed

Sponsor

Merck & Co.

Start

Jul 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1